These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 29344876)

  • 1. Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.
    McKinnon RA; Cook M; Liauw W; Marabani M; Marschner IC; Packer NH; Prins JB
    BioDrugs; 2018 Feb; 32(1):27-52. PubMed ID: 29344876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies.
    Numan S; Faccin F
    Adv Ther; 2018 Sep; 35(9):1295-1332. PubMed ID: 30084060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review.
    Bakalos G; Zintzaras E
    Clin Ther; 2019 Jan; 41(1):155-173.e13. PubMed ID: 30551802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective.
    Kurki P; Barry S; Bourges I; Tsantili P; Wolff-Holz E
    Drugs; 2021 Nov; 81(16):1881-1896. PubMed ID: 34596876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.
    Cohen HP; Blauvelt A; Rifkin RM; Danese S; Gokhale SB; Woollett G
    Drugs; 2018 Mar; 78(4):463-478. PubMed ID: 29500555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
    Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
    Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies.
    Cohen HP; Hachaichi S; Bodenmueller W; Kvien TK; Danese S; Blauvelt A
    BioDrugs; 2022 Sep; 36(5):625-637. PubMed ID: 35881304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.
    Inotai A; Prins CPJ; Csanádi M; Vitezic D; Codreanu C; Kaló Z
    Expert Opin Biol Ther; 2017 Aug; 17(8):915-926. PubMed ID: 28650704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Effectiveness of Multiple Switching Between Originators and Biosimilars: Literature Review and Status Report on Interchangeability.
    Lasala R; Abrate P; Zovi A; Santoleri F
    Ther Innov Regul Sci; 2023 Mar; 57(2):352-364. PubMed ID: 36322326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics: A Systematic Review.
    Chingcuanco F; Segal JB; Kim SC; Alexander GC
    Ann Intern Med; 2016 Oct; 165(8):565-574. PubMed ID: 27479870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
    Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
    Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching Among Biosimilars: A Review of Clinical Evidence.
    Allocati E; Godman B; Gobbi M; Garattini S; Banzi R
    Front Pharmacol; 2022; 13():917814. PubMed ID: 36091837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis.
    Herndon TM; Ausin C; Brahme NN; Schrieber SJ; Luo M; Andrada FC; Kim C; Sun W; Zhou L; Grosser S; Yim S; Ricci MS
    PLoS One; 2023; 18(10):e0292231. PubMed ID: 37788264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review.
    Liu Y; Yang M; Garg V; Wu EQ; Wang J; Skup M
    Adv Ther; 2019 Aug; 36(8):1851-1877. PubMed ID: 31168766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
    Lee S; Lee H; Kim E
    BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review.
    Barbier L; Ebbers HC; Declerck P; Simoens S; Vulto AG; Huys I
    Clin Pharmacol Ther; 2020 Oct; 108(4):734-755. PubMed ID: 32236956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacists' Perspectives of Biosimilars: A Systematic Review.
    Mohd Sani N; Aziz Z; Panickar R; Kamarulzaman A
    BioDrugs; 2022 Jul; 36(4):489-508. PubMed ID: 35776294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.
    Feagan BG; Lam G; Ma C; Lichtenstein GR
    Aliment Pharmacol Ther; 2019 Jan; 49(1):31-40. PubMed ID: 30411382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.